Hinge Health, Inc. (HNGE)
NYSE: HNGE · Real-Time Price · USD
49.41
+0.27 (0.55%)
At close: Jan 8, 2026, 4:00 PM EST
49.62
+0.21 (0.43%)
After-hours: Jan 8, 2026, 7:14 PM EST
Hinge Health Stock Forecast
Stock Price Forecast
The 14 analysts that cover Hinge Health stock have a consensus rating of "Strong Buy" and an average price target of $60.43, which forecasts a 22.30% increase in the stock price over the next year. The lowest target is $45 and the highest is $71.
Price Target: $60.43 (+22.30%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Hinge Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $72 → $70 | Buy | Maintains | $72 → $70 | +41.67% | Jan 8, 2026 |
| Needham | Needham | Strong Buy Reiterates $59 | Strong Buy | Reiterates | $59 | +19.41% | Jan 6, 2026 |
| Barclays | Barclays | Buy Maintains $65 → $60 | Buy | Maintains | $65 → $60 | +21.43% | Jan 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $61 → $65 | Strong Buy | Maintains | $61 → $65 | +31.55% | Nov 5, 2025 |
| Barclays | Barclays | Buy Maintains $62 → $65 | Buy | Maintains | $62 → $65 | +31.55% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
585.31M
from 390.40M
Increased by 49.92%
Revenue Next Year
711.65M
from 585.31M
Increased by 21.59%
EPS This Year
0.87
from -0.88
EPS Next Year
1.57
from 0.87
Increased by 80.38%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 609.1M | 776.9M | ||||
| Avg | 585.3M | 711.7M | ||||
| Low | 561.5M | 647.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 56.0% | 32.7% | ||||
| Avg | 49.9% | 21.6% | ||||
| Low | 43.8% | 10.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.38 | 2.04 | ||||
| Avg | 0.87 | 1.57 | ||||
| Low | -7.37 | 0.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 134.7% | ||||
| Avg | - | 80.4% | ||||
| Low | - | -18.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.